Isolated polypeptide of the toxin A and toxin B proteins of
This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
1. An isolated polypeptide comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4, wherein the sequence identity is determined by Needleman-Wunsch global alignment.
2. The polypeptide of claim 1 , wherein the polypeptide comprises 19 repeating units derived from the C-terminal domain of toxin A of Clostridium difficile.
3. The polypeptide of claim 1 , wherein the polypeptide comprises 23 repeating units derived from the C-terminal domain of toxin B of Clostridium difficile.
4. The polypeptide of claim 1 , wherein the polypeptide consists of the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 4.
5. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier or excipient.
6. An immunogenic or vaccine composition comprising an isolated polypeptide having at least 85% sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 and a pharmaceutically acceptable carrier or excipient, wherein the sequence identity is determined by Needleman-Wunsch global alignment.
7. The composition of claim 6 , wherein the polypeptide comprises 19 repeating units derived from the C-terminal domain of toxin A of Clostridium difficile.
8. The composition of claim 6 , wherein the polypeptide comprises 23 repeating units derived from the C-terminal domain of toxin B of Clostridium difficile.
9. The composition of claim 6 , wherein the polypeptide consists of the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 4.
10. The composition of claim 6 , wherein the composition further comprises a therapeutic agent and is for the prevention and treatment of a C. difficile associated disease (CDAD).
11. The composition of claim 6 , wherein the polypeptide has at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4.
12. The composition of claim 6 , further comprising an adjuvant.
13. The composition of claim 12 , wherein the adjuvant comprises alum.
14. An isolated polypeptide having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4.
15. A pharmaceutical composition comprising the polypeptide of claim 14 and a pharmaceutically acceptable carrier or excipient.